Last reviewed · How we verify
cycle 3: treatment drug
cycle 3: treatment drug is a Small molecule drug developed by Shenzhen TargetRx Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | cycle 3: treatment drug |
|---|---|
| Sponsor | Shenzhen TargetRx Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Dose-escalation of Regorafenib in Advanced Hepatocellular Carcinoma (PHASE2)
- A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) (PHASE3)
- Testing the Combination of an Anti-Cancer Drug, Iadademstat, With Other Anti-Cancer Drugs (Venetoclax and Azacitidine) for Treating AML (PHASE1)
- BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia (PHASE1)
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma (PHASE3)
- A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- cycle 3: treatment drug CI brief — competitive landscape report
- cycle 3: treatment drug updates RSS · CI watch RSS
- Shenzhen TargetRx Co., Ltd. portfolio CI
Frequently asked questions about cycle 3: treatment drug
What is cycle 3: treatment drug?
cycle 3: treatment drug is a Small molecule drug developed by Shenzhen TargetRx Co., Ltd..
Who makes cycle 3: treatment drug?
cycle 3: treatment drug is developed by Shenzhen TargetRx Co., Ltd. (see full Shenzhen TargetRx Co., Ltd. pipeline at /company/shenzhen-targetrx-co-ltd).
What development phase is cycle 3: treatment drug in?
cycle 3: treatment drug is in Phase 1.
Related
- Manufacturer: Shenzhen TargetRx Co., Ltd. — full pipeline
- Compare: cycle 3: treatment drug vs similar drugs
- Pricing: cycle 3: treatment drug cost, discount & access